Haoda Fu

List of Publications by Year
in descending order

46 papers	**1,039** citations	566801 **15** h-index	433756 **31** g-index
46 all docs	**46** docs citations	**46** times ranked	**1574** citing authors

#	Article	IF	Citations
1	Multicategory Angle-Based Learning for Estimating Optimal Dynamic Treatment Regimes With Censored Data. Journal of the American Statistical Association, 2022, 117, 1438-1451.	1.8	6
2	Statistical Inference on the Estimators of the Adherer Average Causal Effect. Statistics in Biopharmaceutical Research, 2022, 14, 392-395.	0.6	2
3	Risk controlled decision trees and random forests for precision Medicine. Statistics in Medicine, 2022, 41, 719-735.	0.8	6
4	Estimating individualized treatment rules for treatments with hierarchical structure. Electronic Journal of Statistics, 2022, 16, .	0.4	1
5	Analysis of recurrent hypoglycemic events. Journal of Biopharmaceutical Statistics, 2021, 31, 5-13.	0.4	0
6	Multi-Armed Angle-Based Direct Learning for Estimating Optimal Individualized Treatment Rules With Various Outcomes. Journal of the American Statistical Association, 2020, 115, 678-691.	1.8	23
7	A General Framework for Treatment Effect Estimators Considering Patient Adherence. Statistics in Biopharmaceutical Research, 2020, 12, 1-18.	0.6	17
8	Multicategory Outcome Weighted Margin-based Learning for Estimating Individualized Treatment Rules. Statistica Sinica, 2020, 30, 1857-1879.	0.2	7
9	Near-optimal Individualized Treatment Recommendations. Journal of Machine Learning Research, 2020, 21, .	62.4	0
10	Quantile regression modeling of latent trajectory features with longitudinal data. Journal of Applied Statistics, 2019, 46, 2884-2904.	0.6	1
11	Trifluridine/tipiracil in metastatic gastric cancer. Lancet Oncology, The, 2019, 20, e8.	5.1	2
12	Modeling the impact of preplanned dose titration on delayed response. Journal of Biopharmaceutical Statistics, 2019, 29, 287-305.	0.4	3
13	Estimating Individualized Treatment Rules for Ordinal Treatments. Biometrics, 2018, 74, 924-933.	0.8	17
14	Power and Commensurate Priors for Synthesizing Aggregate and Individual Patient Level Data in Network Meta-Analysis. Journal of the Royal Statistical Society Series C: Applied Statistics, 2018, 67, 1047-1069.	0.5	10
15	An Algorithm for Generating Individualized Treatment Decision Trees and Random Forests. Journal of Computational and Graphical Statistics, 2018, 27, 849-860.	0.9	13
16	Learning Optimal Personalized Treatment Rules in Consideration of Benefit and Risk: With an Application to Treating Type 2 Diabetes Patients With Insulin Therapies. Journal of the American Statistical Association, 2018, 113, 1-13.	1.8	66
17	Quantifying the totality of treatment effect with multiple event–time observations in the presence of a terminal event from a comparative clinical study. Statistics in Medicine, 2018, 37, 3589-3598.	0.8	10
18	Estimating individualized optimal combination therapies through outcome weighted deep learning algorithms. Statistics in Medicine, 2018, 37, 3869-3886.	0.8	8

#	Article	IF	Citations
19	Bayesian isotonic regression dose–response model. Journal of Biopharmaceutical Statistics, 2017, 27, 824-833.	0.4	5
20	Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio. JAMA Oncology, 2017, 3, 1692.	3.4	179
21	Risk Factors for Nocturnal Hypoglycemia in Insulin-treated Patients With Type 2 Diabetes: A Secondary Analysis of Observational Data Derived From an Integrated Clinical Trial Database. Clinical Therapeutics, 2017, 39, 1790-1798.e7.	1.1	16
22	Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249. Diabetes Care, 2016, 39, e199-e200.	4.3	5
23	Crossover design and its application in late–phase diabetes studies. Journal of Diabetes, 2016, 8, 610-618.	0.8	5
24	Perspectives on Some Controversies in Cardiovascular Disease Risk Assessment in the Pharmaceutical Development of Glucose-Lowering Medications. Diabetes Care, 2016, 39, S219-S227.	4.3	10
25	Estimating optimal treatment regimes via subgroup identification in randomized control trials and observational studies. Statistics in Medicine, 2016, 35, 3285-3302.	0.8	37
26	Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care, 2016, 39, 1241-1249.	4.3	154
27	Hypoglycemic events analysis via recurrent time-to-event (HEART) models. Journal of Biopharmaceutical Statistics, 2016, 26, 280-298.	0.4	6
28	Incorporation of individual–patient data in network meta–analysis for multiple continuous endpoints, with application to diabetes treatment. Statistics in Medicine, 2015, 34, 2794-2819.	0.8	27
29	Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies. Annals of Internal Medicine, 2015, 163, 127-134.	2.0	162
30	Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis. Diabetes Therapy, 2015, 6, 317-328.	1.2	9
31	Detecting outlying trials in network meta–analysis. Statistics in Medicine, 2015, 34, 2695-2707.	0.8	34
32	Estimate variable importance for recurrent event outcomes with an application to identify hypoglycemia risk factors. Statistics in Medicine, 2015, 34, 2743-2754.	0.8	3
33	Identifying factors associated with hypoglycemia-related hospitalizations among elderly patients with T2DM in the US: a novel approach using influential variable analysis. Current Medical Research and Opinion, 2014, 30, 1787-1793.	0.9	28
34	Guidance on the implementation and reporting of a drug safety Bayesian network meta–analysis. Pharmaceutical Statistics, 2014, 13, 55-70.	0.7	24
35	Joint modeling of progression–free survival and overall survival by a Bayesian normal induced copula estimation model. Statistics in Medicine, 2013, 32, 240-254.	0.8	19
36	A randomized, cross-over comparison of preference between two reusable insulin pen devices in pen-naïve adults with diabetes. Current Medical Research and Opinion, 2013, 29, 465-473.	0.9	5

#	Article	IF	Citations
37	Bayesian Adaptive D-Optimal Design with Delayed Responses. Journal of Biopharmaceutical Statistics, 2013, 23, 559-568.	0.4	1
38	Evaluating and utilizing probability of study success in clinical development. Clinical Trials, 2013, 10, 407-413.	0.7	44
39	Identifying Potential Adverse Events Dose-Response Relationships Via Bayesian Indirect and Mixed Treatment Comparison Models. Journal of Biopharmaceutical Statistics, 2013, 23, 26-42.	0.4	6
40	Bayesian indirect and mixed treatment comparisons across longitudinal time points. Statistics in Medicine, 2013, 32, 2613-2628.	0.8	15
41	Ease of Use of Two Reusable, Half-Unit Increment Dosing Insulin Pens by Adult Caregivers of Children with Type 1 Diabetes: A Randomized, Crossover Comparison. Journal of Diabetes Science and Technology, 2013, 7, 582-583.	1.3	6
42	A Bayesian approach to the statistical analysis of device preference studies. Pharmaceutical Statistics, 2012, 11, 149-156.	0.7	4
43	Bayesian Optimal Adaptive Designs for Delayed-Response Dose-Finding Studies. Journal of Biopharmaceutical Statistics, 2011, 21, 888-901.	0.4	5
44	Bayesian Adaptive Dose-Finding Studies with Delayed Responses. Journal of Biopharmaceutical Statistics, 2010, 20, 1055-1070.	0.4	28
45	High-dimensional pseudo-logistic regression and classification with applications to gene expression data. Computational Statistics and Data Analysis, 2007, 52, 452-470.	0.7	8
46	Masking effects on linear regression in multi-class classification. Statistics and Probability Letters, 2006, 76, 1800-1807.	0.4	2